Lupus & antiphospholipid syndrome
Tumour-associated antigens in systemic lupus erythematosus: association with clinical manifestations and serological indicators
Authors' conclusion
The positivity rates and serum levels of some TAAs were elevated in SLE, and thrombocytopenia and SCR levels were independent risk factors for TAA positivity.
Study context
- Population
- SLE patients with serum tumour-associated antigens (TAAs) (alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), CA19–9, CA125, CA15–3, CYFRA21–1) from electronic medical records, and matched healthy subjectsmatched cohort
- Participants
- 149 vs 149
- Exposure
- SLE patients vs age- and sex-matched healthy subjects; SLE with vs without TAA positivity
- SLEn = 149
- Controln = 149reference
- Outcome
- Relationship of TAAs with clinical manifestations and serological markers of SLE; TAA positivity = serum level above upper limit of reference range
Methodological detailsage- and sex-matched healthy controls, logistic regression
- Age- and sex-matched healthy controls
- Logistic regression
Main finding
As reported in the abstract
- Higher positivity rates for CA19-9 and CYFRA21-1 in SLE vs healthy controls
- Elevated serum levels of CA125, CA15-3 and CYFRA21-1 in SLE vs healthy controls
Observational data: associations, not effects.
Further findings
Characteristics of SLE patients with vs without TAA positivity
- TAA-positive patients older, with higher prevalence of serous effusion, pericardial effusion, albuminuria and thrombocytopenia, and lower anti-dsDNA positivity
- Higher serum creatinine, blood urea nitrogen, glutamic oxalate transaminase and 24-h urinary protein; lower platelet count and serum albumin in TAA-positive patients
- Thrombocytopenia and serum creatinine independent risk factors for TAA positivity (logistic regression)
CA125 and SLE disease activity
- CA125 positivity rate and serum CA125 levels associated with SLE disease activity
Original publication
Tumour-associated antigens in systemic lupus erythematosus: association with clinical manifestations and serological indicators. Rheumatology (Oxford). Published 15 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →